Respiratory tract infections (RTIs) are a huge burden in terms of mortality and morbidity worldwide. To improve the management of the bacterial infections of the respiratory tract, the institution of an appropriate antimicrobial therapy as soon as possible has also been shown to be a key element for reducing morbidity and mortality. The aim of our project is to develop a panel of dedicated rapid diagnostic tests to allow the medical staff to link antibiotic prescription on evidence-based diagnosis. In our 3 year project, combining the Multiplex Ligation-dependent Probe Amplification (MLPA) and microfluidic technologies will allow to address the question of viral or bacterial origin. In the case of a bacteria, a second step will allow to identify which bacteria is of interest with its virulence factors and resistance mechanisms. This new tool will be developed for efficient use in clinical settings in order to allow for a better antibiotic resistance management. Several direct impacts will be observed either on public health (decrease of antibiotic pressure), efficiency of treatment for patients (decrease of infectivity and speed in accurate treatments), for diagnostic laboratories (improve in turn around time), for SMEs (better competitiveness) and more generaly on technological innovations.